top of page
  • Recruiting

NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma NDMM

Updated: Jan 27

  • SWOG - S2209 - Southwest Oncology Group

  • NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment


swog-s2209

NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment


This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail or intermediate-fit based on age, comorbidities, and functional status.


Sponsor


Collaborator

 

ClinicalTrials.gov Identifier: NCT05561387

Official Title: A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance

First Posted : September 30, 2022

Click here for details on ClinicalTrials.gov

 
 

Drug: Bortezomib

Drug: Daratumumab and Hyaluronidase-fihj

Drug: Dexamethasone

Drug: Lenalidomide

Other: Quality-of-Life Assessment

Other: Questionnaire Administration

 

Patient Information - FDA Approved Drugs Multiple Myeloma

 

Location

United States

 

Comments


Commenting has been turned off.
Posts Archive
bottom of page